Lavipharm S.A.

€1.45As of Sun 8 Nov 2026, 12:00 UTC
ATH:LAVIHealthcare
Country Greece
PE (Fwd) •••
TSR 10Y CAGR 18.56%
Div yield 1.38%
ROE 10.22%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 1.30
PE TTM 44.15
TSR TTM 81.98%
Mkt cap €247.6M
ROIC 7.49%
SE Grade™
Value
Quality
Moat
Consensus
Reference
€1.85
27.41%
177.22%
Hold 4|11|12|4|3
4Q25
1Q26
2Q26
3Q26
Earnings per share€
0.01
0.01
0.02
0.01
13.61%
24.36%
24.54%
9.37%
Revenue€M
24.67
23.99
25.07
25.79
6.40%
4.44%
5.87%
3.56%
Peers (US$278.0M)
Cap (US$)
PE
30.68M
—
15.38M
5.562x
Capital
TTM
5Y
10Y
Leveragex
0.650
0.072
0.068
EBIT/Intx
3.358
1.016
0.791
Own earn%
(112.82)
(5.29)
(22.35)
Sh yield%
25.30
28.28
31.41
Owners
Insiders/Inst%
10.72
56.19
Short interest%
5.00
SBC / revenue%
2.16
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
7–11
$1 testx
0.0
Incr. ROIC%
3